Friday 28th July 2023 13:00 - 14:00 (BST)
The UK is one of Europe’s largest markets but has long had the unenviable reputation of being “low and slow” for the uptake of new medicines. In recent months, however, the government has introduced a range of ground-breaking measures to expedite access, while the regulatory and HTA agencies have been working with the NHS to develop innovative approaches to make promising new drugs widely available without delay. These changes are helping to make the UK one of the most inventive access environments in Europe, with a willingness to explore new ideas in partnership with pharmaceutical companies. What lessons can the industry learn from the UK experience?
28th Jul 2023 13:00 – 14:00 (BST)